Anakinra for neutrophilic pustular skin disease

阿那白滞素（Anakinra）治疗中性粒细胞性脓疱性皮肤病

• 批准号: 10262363
• 负责人: Edward Cowen
• 金额: $ 10.93万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10262363
• 关键词: Biological; Clinical; Collaborations; Disease; Enrollment; Goals; Interleukin-1; Laboratories; Outcome; PET/CT scan; Pathway interactions; Patients; Protocols documentation; Pustular psoriasis; Sampling; Serum; Therapeutic; Tissues; Treatment Protocols; anakinra; cardiovascular disorder risk; design; neutrophil; skin disorder

To date, 17 patients have enrolled on this treatment protocol. A goal of 25-30 patients has been established to determine if anakinra has efficacy for pustular neutrophilic skin disease. In addition to the clinical outcomes, tissue and serum samples are being sent to the lab of Raphaela Goldbach-Mansky, Maria Morasso, Alison McBride, and Nehal Mehta in order to further investigate the biologic pathways responsible for pustular psoriasis, including risk of cardiovascular disease as assessed by PET/CT.

迄今为止，已有 17 名患者参加了该治疗方案。已确定 25-30 名患者的目标，以确定阿那白滞素是否对脓疱性中性粒细胞性皮肤病有效。除了临床结果外，组织和血清样本还被送往 Raphaela Goldbach-Mansky、Maria Morasso、Alison McBride 和 Nehal Mehta 的实验室，以进一步研究导致脓疱型银屑病的生物学途径，包括心血管疾病的风险通过 PET/CT 评估。